The relevance of TNFα antagonists in decreasing eosinophil and/or basophil counts in vivo is unclear; however, anti-TNFα agents have been reported to decrease sputum histamine levels and improve asthma outcomes, airway hyper-responsiveness, and exacerbation rates [34,35]. This evidence concerns the gene TNF and asthma.